Summit Therapeutics (LSE:SUMM) Debt-to-Equity : 2.48 (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Summit Therapeutics Debt-to-Equity?

Summit Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was £2.91 Mil. Summit Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was £83.28 Mil. Summit Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was £34.79 Mil. Summit Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 2.48.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Summit Therapeutics's Debt-to-Equity or its related term are showing as below:

LSE:SUMM' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.41 Med: 0.03 Max: 4.1
Current: 2.48

During the past 13 years, the highest Debt-to-Equity Ratio of Summit Therapeutics was 4.10. The lowest was -0.41. And the median was 0.03.

LSE:SUMM's Debt-to-Equity is ranked worse than
91.21% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs LSE:SUMM: 2.48

Summit Therapeutics Debt-to-Equity Historical Data

The historical data trend for Summit Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Debt-to-Equity Chart

Summit Therapeutics Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.01

0.03

4.10

1.37

Summit Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.78	0.90	1.07	1.37	2.48

Competitive Comparison of Summit Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Summit Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Summit Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Debt-to-Equity falls into.

Summit Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Summit Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.219	+	81.599)	/	61.377
	=	1.37

Summit Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.911	+	83.283)	/	34.793
	=	2.48

Summit Therapeutics (LSE:SUMM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Summit Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics (LSE:SUMM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SMMT:USA

Address

2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025

Website

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics (LSE:SUMM) Headlines

No Headlines